OncoMatch/Clinical Trials/NCT05827523

Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (FOCUS / KOV-HIPEC-04)

Is NCT05827523 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Cisplatin for ovarian cancer.

Phase 3RecruitingNational Cancer Center, KoreaNCT05827523Data as of May 2026

Treatment: Cisplatin — Primary stage III-IV epithelial ovarian cancer randomizing between interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC)

Check if I qualify

Extracted eligibility criteria

Cancer type

Ovarian Cancer

Disease stage

Required: Stage FIGO STAGE III, FIGO STAGE IV (FIGO)

FIGO stage III-IV

Prior therapy

Must have received: neoadjuvant chemotherapy

treated with three cycles of neoadjuvant chemotherapy

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify